AUTHORS
Mackenzie Emily Lemieux, MD, Spencer Gilbert, PharmD2, Stephen Jenkins, MD3, Sara Vazquez, PharmD4, Ming Lim, MBBCh, MS5
AFFILIATIONS
1 University of Utah Huntsman Center, Salt Lake City, United States
2 University of Utah Huntsman Center, Salt Lake City, United States
3 University of Utah Huntsman Center, Salt Lake City, United States
4 University of Utah Huntsman Center, Salt Lake City, United States
5 University of Utah Huntsman Center, Salt Lake City, United States
ABSTRACT
Background
Abnormal uterine bleeding (AUB) occurs in two thirds of reproductive age women on anticoagulation, negatively impacting their quality of life (de Jong et al. 2022; Liu et al. 2007). Management of estrogen-containing hormonal therapies in women newly diagnosed with venous thromboembolism (VTE) remains inconsistent despite contemporary guidance supporting continuation of hormonal therapy with initiation of therapeutic anticoagulation (Klok et al. 2017; Martinelli et al. 2016; Samuelson Bannow et al. 2025). Inappropriate discontinuation of estrogen-containing hormonal therapy increases rates of AUB, iron deficiency, and anemia (Samuelson Bannow et al. 2025). We seek to determine the current practice pattern for hormonal therapy management among reproductive-age women diagnosed with acute VTE and its associated outcomes.
Methods
We performed a single-center retrospective cohort study of reproductive age women (18–55 years) diagnosed with acute VTE at the University of Utah Health between January 2015 and December 2024. VTE events were identified using validated natural language processing algorithms applied to radiographic reports (Johnson et al. 2021; Woller et al. 2021). Women prescribed oral anticoagulation within 7 days of VTE diagnosis and estrogen-containing hormonal therapy within 1 year prior to the VTE event were included. For individuals with multiple VTE events during the study period, only the earliest qualifying VTE event was included.
Clinical, laboratory, and prescribing data were extracted from the electronic medical record and supplemented by manual chart review. Primary outcomes included rates of estrogen-containing hormonal therapy continuation, discontinuation, or transition to a different hormonal therapy following the VTE event. Secondary outcomes included rates of AUB, emergency department (ED) visits for AUB, anemia (defined as <12 g/dL), iron deficiency (defined as ferritin <30 ng/mL), and laboratory monitoring for anemia and iron deficiency within 3 months post-VTE diagnosis.
Results
Among 870 reproductive-age women prescribed oral anticoagulation following an acute VTE, 83 women met inclusion criteria. The median age was 32 years (range 19–54), and 52% (n= 43) had a history of AUB. Estrogen-containing hormonal therapy was discontinued in 45% (n=37) of women, continued in 18% (n=15), discontinued with immediate (<1 week) transition to a non-estrogen containing alternative contraceptive strategy in 21% (n = 17), and discontinued with delayed (>=1 week) transition to a non-estrogen containing alternative in 16% (n=13). Among women who immediately transitioned therapy, most initiated progestin-only pills (65%, n=11), while most women with delayed transitions had intrauterine devices (IUDs) placed (56%, n=7).
Laboratory monitoring for iron deficiency and anemia following the VTE event was limited. Hemoglobin assessment within 3 months occurred in only 36% (n=30) of women, while ferritin testing occurred in 17% (n=14). Among women who underwent post-VTE laboratory testing, anemia was identified in 30% (n = 9 out of 30) and iron deficiency in 50% (n = 7 out of 14).
AUB occurred in 45% of women during the first 3 months post-VTE. Rates of AUB were lower among women who continued estrogen-containing hormonal therapy compared with those who discontinued, immediately transitioned, or had a delayed transition of their estrogen-containing hormone therapy (27% vs 35%, 60%, 77% respectively, p=0.018).
Conclusions
Discontinuation of estrogen-containing hormonal therapy at time of VTE diagnosis remains common despite contemporary evidence supporting continuation with initiation of therapeutic anticoagulation. Rates of post-VTE laboratory monitoring for anemia and iron deficiency were also low, despite high rates of AUB and clinically significant hematologic abnormalities among those tested. These findings identify substantial gaps in antithrombotic stewardship and monitoring of iron deficiency among reproductive-age women diagnosed with acute VTE.
DISCLOSURES
Mackenzie Emily Lemieux, MD: No relevant conflicts of interest to declare.